ShenZhen YUTO Packaging Technology (002831.SZ) plans to repurchase company shares for RMB 200 million to RMB 400 million.
YUTO Packaging Technology (002831.SZ) announced that the company plans to repurchase part of its publicly held shares through centralized bidding using its own funds and/or self-raised funds. The repurchased shares will be used for employee stock ownership plans or equity incentives. The total amount for the share repurchase shall be no less than RMB 200 million (inclusive) and no more than RMB 400 million (inclusive), with the repurchase price not exceeding RMB 41.13 per share.
ShenZhen YUTO Packaging Technology (002831.SZ) announced that the company plans to repurchase a portion of its publicly held shares through centralized bidding transactions using its own funds and/or self-raised funds. The repurchased shares will be used for employee stock ownership plans or equity incentives. The total amount for the share repurchase shall be no less than (inclusive) RMB 200 million and no more than (inclusive) RMB 400 million, with the repurchase price not exceeding RMB 41.13 per share.
Related Articles
SHENZHEN INVEST (00604) third-quarter contracted sales of approximately RMB 1.814 billion
Hwatsing Technology (688120.SH) Chairman proposes to repurchase company shares for RMB 50 million to RMB 100 million.
GlaxoSmithKline plc Sponsored ADR (GSK.US), Inovio (INO.US), and Agios (AGIO.US) are clustered in the queue awaiting review, as U.S. innovative drugs usher in an FDA approval window.
SHENZHEN INVEST (00604) third-quarter contracted sales of approximately RMB 1.814 billion
Hwatsing Technology (688120.SH) Chairman proposes to repurchase company shares for RMB 50 million to RMB 100 million.
GlaxoSmithKline plc Sponsored ADR (GSK.US), Inovio (INO.US), and Agios (AGIO.US) are clustered in the queue awaiting review, as U.S. innovative drugs usher in an FDA approval window.
